A
Adaptive Phage Therapeutics
Provides therapeutic services intended to treat multi-drug resistant pathogenic bacteria
About Adaptive Phage Therapeutics
Adaptive Phage Therapeutics (APT) is a clinical stage company focused on developing precision phage therapy to address the growing threat of multi-drug resistant (MDR) bacterial infections. Founded on pioneering research by NIH scientist Dr. Carl R. Merril and further explored by the US Navy's Biological Defense Research Directorate, APT aims to provide effective therapeutic responses where traditional antibiotics fail. The company operates in the biotechnology and healthcare market, primarily serving hospitals, healthcare providers, and patients affected by MDR infections. APT's business model revolves around the development and commercialization of phage-based treatments, including a phage susceptibility test in collaboration with the Mayo Clinic. Revenue is generated through clinical trials, partnerships, and eventual commercialization of their therapies.
Source: Dealroom company dataAt a glance
- Status
- Acquired
- Founded
- 2016
- Headquarters
- Gaithersburg, United States
- Employees
- 10
- Open positions
- None listed
- Dealroom signal
- 63.5/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Spinout, Biotech and Pharma, DT and LS, science-based
- Technology
- Deep Tech
- Business model
- Manufacturing
- Client focus
- B2B
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| ACQUISITIONOther financing | Mar 2024 | $0 | — | BiomX | ↗ |
| SERIES BOther financing | Jun 2023 | $12M | $204M | AMR Action Fund | ↗ |
Growth signals
Latest recorded traffic for Adaptive Phage Therapeutics is 130 monthly website visits, down 89.2% over the last three months. Adaptive Phage Therapeutics's team declined 60% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
| Company | Headquarters | Status | Employees | Total funding | Valuation |
|---|---|---|---|---|---|
| Siloam Springs, United States | Operational | — | $20M | $80M | |
Brink TherapeuticsUnlocking in vivo cell therapy with the next generation of gene editing technology |
Saint-Mandé, France | Operational | |||
VectiopepDevelop cancer immunotherapy |
Tartu, Estonia | Operational | |||
Kelonia TherapeuticsDeveloping a new wave of genetic medicines using its next generation vivo gene delivery platform |
Boston, United States | Acquired | |||
Ysotope TheranosticsTargeted radiopharmaceuticals for precision oncology |
Madrid, Spain | Operational | |||
NadmedThe standard in NAD testing |
Helsinki, Finland | Operational | |||
PRISM BioLabPRISM BioLab is a biotechnology company with PepMetics Technology, a proprietary drug discovery platform |
Fujisawa, Japan | Operational | |||
Swan NeuroTechDeveloping biodegradable implants that deliver drugs to promote nerve regeneration after injury. |
Pittsburgh, United States | Operational |
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Adaptive Phage Therapeutics in the Gaithersburg ecosystem
The Adaptive Phage Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed2 investors entered at this stage
US Department of War
Military Health System
Series A5 investors entered at this stage
Alexandria Equities
Alexandria Venture Investments
Mayo Clinic
Deerfield
AMR Action Fund
Other known investors2 additional known investors
BiomX
National Institutes of Health
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Adaptive Phage Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Adaptive Phage Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.








